<div class="white-sheet">
	<div class="content-slide">

		<div class="title-bar red"></div>

		<div class="wrapper slide-3-1-2">

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>			
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>	
			</div>

			<div class="slide-title red">
				Eltrombopag interacts with the thrombopoietin receptor
			</div>


			<div class="content-container">
				

				<div class="content-left">
					
					<ul>
						<li><span>Eltrombopag is a non-peptide TPO-R agonist that targets the TPO-R<sup>1–4</sup></span>
							<ul>
								<li><span>Binds only to human and chimpanzee TPO-Rs<sup>2,3</sup></span></li>
								<li><span>TPO-R is also known as c-Mpl</span></li>
							</ul>
						</li>
						<li><span>Eltrombopag interacts with the transmembrane domain of the human TPO-R, and initiates signalling cascades that induce proliferation and differentiation of megakaryocytes from bone marrow progenitor cells<sup>4</sup></span></li>
						<li><span>Eltrombopag does not compete with endogenous TPO for receptor binding in vitro<sup>3</sup></span>
							<ul>
								<li><span>Binds to a different region of TPO-R than that targeted by endogenous TPO and TPO peptide mimetics<sup>5</sup></span></li>
								<li><span>Effects are at least additive to those of endogenous TPO, both in tissue culture and in preclinical animal models<sup>3</sup></span></li>
							</ul>
						</li>
					</ul>

				</div>

				<div class="content-right">
					
					<div class="red-label">Stimulation of platelet production by TPO<sup>3</sup></div>

					<img src="media/images/slide_3-1-2/picture1.png" alt="">

					<p class="small-print">TPO-R is encoded by the c-mpl gene.<sup>6</sup> TPO-R can be found on the surface of megakaryocyte precursor cells, megakaryocytes, platelets, stem cells and early bone marrow progenitor cells of all lineages<sup>5</sup></p>

				</div>

				

			</div>

		</div>

		<div class="information-overlay overlay">

			<header>Chemical structure of eltrombopag</header>
				
			<ul>
				<li><span>Thrombopoietin receptor (TPO-R) is thought to exist as an inactive preformed dimer with a proximal (CRH-2) and distal (CRH-1) cytokine receptor homology domain<sup>6</sup></span></li>
				<li><span>Binding of a endogenous TPO or of a TPO peptide mimetic (e.g. romiplostim) to the distal CRH-1, or binding of eltrombopag to the transmembrane region, leads to receptor conformational changes<sup>6</sup></span>
					<ul>
						<li><span>Several signal-transduction pathways are activated that increase platelet production</span></li>
					</ul>
				</li>
				<li><span>Eltrombopag induces phosphorylation of STAT5, but not STAT3 or AKT in more committed progenitor cells<sup>7</sup></span>
					<ul>
						<li><span>Recombinant TPO activates these pathways in progenitor cells at a more advanced stage of differentiation<sup>7</sup></span>
							<ul>
								<li><span>The STAT3 and AKT pathways may not be significant for the differentiation of CD34+ cells to CD41+ cells<sup>7</sup></span></li>
							</ul>
						</li>
						<li><span>This difference highlights the target cell type of eltrombopag and its potential to stimulate progenitor stem cell proliferation and restore haematopoiesis</span></li>
					</ul>
				</li>
				<li><span>It is also known that eltrombopag does not increase platelet aggregation or increase platelet surface expression of activation markers, unlike endogenous TPO<sup>8,9</sup></span>
					<ul>
						<li><span>Aplastic anaemia is characterised by a very limited number of haematopoietic stem progenitor cells (HSPCs), due to immune-mediated attack on the bone</span>
							<ul>
								<li><span>Several preclinical experiments have shown the positive influence of TPO and TPO-R on the expansion of HSPC within the bone marrow<sup>10–13</sup></span></li>
								<li><span>Multilineage bone marrow failure has been reported in patients who have congenital amegakaryocytic thrombocytopenia with mutations of the MpL receptor<sup>14</sup></span></li>
							</ul>
						</li>
					</ul>
				</li>
				

			</ul>

		</div>

		<div class="references-overlay overlay">

			<header>References</header>
				
			<ol>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Erickson-Miller C <i>et al. Exp Hematol</i> 2005;33:85</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Bussel JB & Pinheiro MP. In <i>Hematopoietic Growth Factors in Oncology</i>. 2011</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Kuter DJ <i>et al. Seminars Hematol</i> 2010;47:243</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Kuter DJ. <i>Blood</i> 2007;109:4607</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Cook L <i>et al. Drug Des Devel Ther</i> 2010;4:139 </span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Stasi R <i>et al. Expert Opin Drug Discov</i> 2009;4:85</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Sun H <i>et al. Stem Cell Res</i> 2012;9:77</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Psaila B <i>et al. Blood</i> 2012;119:4066</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Jenkins JM <i>et al. Blood</i> 2007;109:4739</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Zeigler FC <i>et al. Blood</i> 1994;84:4045</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Alexander WS <i>et al. Blood</i> 1996;87:2162</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Kimura S <i>et al. Proc Natl Acad Sci USA</i> 1998;95:1195</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Qian H <i>et al. Cell Stem Cell</i> 2007;1:671</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module2/AlterB-HematolAmSocHematolEducProgram -v2007p29.pdf"><span>Geddis AE. <i>Pediatr Blood Cancer</i> 2011;57:199</span></li>
			</ol>

		</div>

	</div>
</div>